Condition
Castration Resistant Prostatic Neoplasms
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Terminated2
Completed1
Withdrawn1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05252390Phase 1Terminated
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT04381832Phase 1Completed
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
NCT04541225Phase 1Terminated
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
NCT05191017Phase 1Withdrawn
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Showing all 4 trials